83
Participants
Start Date
July 31, 2014
Primary Completion Date
May 31, 2020
Study Completion Date
January 31, 2021
Placebo
Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.
Bupropion XL
Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.
Abstinence Initiation
Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.
Relapse Prevention
Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.
Behavioral Pharmacology Research Unit, Baltimore
Institute for Behavioral Resources, Baltimore
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins University
OTHER